-
Pazopanib, sold
under the
brand name Votrient, is an anti-cancer
medication marketed worldwide by Novartis. It is a
potent and
selective multi-targeted...
- and
doxorubicin combination/gemcitabine and docetaxel/trabectedin;
pazopanib is the
targeted therapy used in
metastatic leiomyosarcoma as
second line...
- This is a list of
adverse effects of the anti-cancer drug
pazopanib,
sorted by
frequency of occurrence. Very
common (>10% incidence)
adverse effects include:...
- interferon),
kinase inhibitors (temsirolimus, sunitinib, sorafenib,
pazopanib) and anti-angiogenic
therapies (bevacizumab). "Clear cell carcinoma"....
-
tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and
pazopanib (some of
these therapies target VEGF
receptors rather than the VEGFs)...
- the Stem Book.
Examples are: -anib for
angiogenesis inhibitors (e.g.
pazopanib) -anserin for
serotonin receptor antagonists,
especially 5-HT2 antagonists...
-
Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies:...
-
Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies:...
-
progressive and
locally advanced differentiated thyroid cancer (DTC).
Pazopanib and
axitinib are used
orally for the
treatment of
advanced renal cell...
-
Axitinib Crenolanib Imatinib Lenvatinib Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies:...
